pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Amvuttra
drug
save

vutrisiran

Marketedupdated 6mo ago
by $ALNY ALNYLAM PHARMACEUTICALS, INC.
Approved
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying vutrisiran

  • phase3TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathyrecruitingn=125
  • phase3A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathyenrolling by invitationn=700
  • phase3HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathyactive not recruitingn=655
  • phase3HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)completedn=164

Patent cliff

source: FDA Orange Book
first barrier falls
Jun 13, 2027
205 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (13)

  • Jul 28, 2036compositionUS 10208307
  • Jul 28, 2036compositionUS 10683501
  • Jul 28, 2036compositionUS 11286486
  • Jul 28, 2036compositionUS 12049628
  • Aug 14, 2035compositionUS 10612024
  • Aug 14, 2035compositionUS 11401517
  • Nov 16, 2032compositionUS 10570391
  • Nov 16, 2032compositionUS 9399775
  • Dec 12, 2029compositionUS 81060223.1y
  • Dec 4, 2028compositionUS 108067912.0y
  • Dec 4, 2028compositionUS 88289562.0y
  • Dec 4, 2028compositionUS 93705812.0y
  • Aug 24, 2028compositionUS 101319071.8y

FDA exclusivities (3)

  • Jun 13, 2029ODE-212Orphan Drug (7y)2.6y
  • Mar 20, 2028I-964Indication (3y)1.3y
  • Jun 13, 2027NCENew Chemical Entity (5y)205d

News(10)

  • BioSpace 40 Under 40 winners Paull, Zhang let patients with rare disease lead the way at BridgeBio
    BridgeBio has produced two young leaders on BioSpace’s 2026 40 Under 40 list. Morgan Paull and Christine Zhang attribute their early success to the company’s unique hub-and-spoke model and a drive…
    biospace · 3d ago
  • Deep dive: Cardiovascular calamities and catalysts
    BioSpace reviews upcoming cardiovascular milestones after a summer of missed targets.
    biospace · 6d ago
  • STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem
    Alnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.
    stat · 7d ago
  • Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
    The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.
    biopharma_dive · 13d ago
  • Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
    AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.
    biopharma_dive · 17d ago
  • BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight
    If approved, BridgeBio Pharma’s BBP-418—which, according to one Jefferies analyst, boasts “pretty darn compelling” data—would be the first therapy for limb-girdle muscular dystrophy. The FDA has an…
    biospace · 17d ago
  • ‘We need to do better,’ Alnylam CEO admits, as uncertainty looms over transthyretin franchise
    Alnylam shares dropped by a quarter on Thursday, with analysts suggesting the decline puts the RNAi specialist within range for a takeout.
    biospace · 20d ago
  • Alnylam bulls and bears fight it out after business-shaking guidance cut
    While Alnylam’s recent reduced revenue guidance spooked investors, analysts remain broadly bullish on the biotech’s commercial prospects.
    biospace · 1mo ago
  • 5 biotechs braving the commercial waters with product launches
    A growing number of biotechs are entering the market with newly launched medicines, a pattern indicative of “improving capital markets,” according to Jefferies’ Andrew Tsai.
    biospace · 2mo ago
  • ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
    At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.
    biopharma_dive · 2mo ago
view all news mentions →
brand
Amvuttra
generic
vutrisiran
indication
Familial Amyloid Cardiomyopathy
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 5h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?